Trending

graft versus host disease

Kiadis sheds half its staff as lead cell therapy bombs

Kiadis sheds half its staff as lead cell therapy bombs

Dutch biotech Kiadis Pharma has abandoned its lead cell therapy and axed half its workforce after a failed

X

Kiadis sheds half its staff as lead cell therapy bombs

https://pharmaphorum.com/news/kiadis-sheds-half-its-staff-as-lead-cell-therapy-bombs/

Janssen/AbbVie drug approved in graft-versus-host disease

Janssen/AbbVie drug approved in graft-versus-host disease

First use for Imbruvica outside blood cancer.

X

Janssen/AbbVie drug approved in graft-versus-host disease

https://pharmaphorum.com/news/imbruvica-drug-approved-graft-versus-host-disease/

Imbruvica granted fourth Breakthrough status

Imbruvica granted fourth Breakthrough status

The drug is also granted Orphan Drug Designation by the FDA.

X

Imbruvica granted fourth Breakthrough status

https://pharmaphorum.com/news/abbvies-imbruvica-granted-breakthrough-therapy-designation-cgvhd/

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com